These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 6149594)

  • 21. Characterization of 6-methoxyflavanone as a novel anxiolytic agent: A behavioral and pharmacokinetic approach.
    Akbar S; Subhan F; Karim N; Aman U; Ullah S; Shahid M; Ahmad N; Fawad K; Sewell RD
    Eur J Pharmacol; 2017 Apr; 801():19-27. PubMed ID: 28257822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Major tranquillizers can be distinguished from minor tranquillizers on the basis of effects on marble burying and swim-induced grooming in mice.
    Broekkamp CL; Rijk HW; Joly-Gelouin D; Lloyd KL
    Eur J Pharmacol; 1986 Jul; 126(3):223-9. PubMed ID: 2875886
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of the accelerating rotarod for assessment of motor performance decrement induced by potential anticonvulsant compounds in nerve agent poisoning.
    Capacio BR; Harris LW; Anderson DR; Lennox WJ; Gales V; Dawson JS
    Drug Chem Toxicol; 1992; 15(3):177-201. PubMed ID: 1425360
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anticonvulsant, anxiolytic and sedative activities of the aqueous root extract of Securidaca longepedunculata Fresen.
    Adeyemi OO; Akindele AJ; Yemitan OK; Aigbe FR; Fagbo FI
    J Ethnopharmacol; 2010 Jul; 130(2):191-5. PubMed ID: 20435127
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Riluzole produces distinct anxiolytic-like effects in rats without the adverse effects associated with benzodiazepines.
    Sugiyama A; Saitoh A; Iwai T; Takahashi K; Yamada M; Sasaki-Hamada S; Oka J; Inagaki M; Yamada M
    Neuropharmacology; 2012 Jun; 62(8):2489-98. PubMed ID: 22377384
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of the anxiolytic and sedative profile of JM-20: a novel benzodiazepine-dihydropyridine hybrid molecule.
    Figueredo YN; Rodríguez EO; Reyes YV; Domínguez CC; Parra AL; Sánchez JR; Hernández RD; Verdecia MP; Pardo Andreu GL
    Neurol Res; 2013 Oct; 35(8):804-12. PubMed ID: 23651620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-benzodiazepine anxiolytics: potential activity of phenylpiperazines without 3H-diazepam displacing action.
    Lloyd KG; Depoortere H; Scatton B; Schoemaker H; Zivkovic B; Manoury P; Langer SZ; Morselli PL; Bartholini G
    Pharmacol Biochem Behav; 1985 Oct; 23(4):645-52. PubMed ID: 2866545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Validation of a modified mirrored chamber sensitive to anxiolytics and anxiogenics in mice.
    Kliethermes CL; Finn DA; Crabbe JC
    Psychopharmacology (Berl); 2003 Sep; 169(2):190-7. PubMed ID: 12783153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the predictive validity of the mirror chamber and elevated plus maze tests in mice.
    Paterson NE; Iwunze M; Davis SF; Malekiani SA; Hanania T
    J Neurosci Methods; 2010 Apr; 188(1):62-70. PubMed ID: 20149823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Behavioral effects of agents active at the gamma-aminobutyric acid receptor complex in the staircase paradigm.
    Weizman R; Paz L; Peter Y; Toren P; Pick CG
    Brain Res; 2001 May; 901(1-2):137-42. PubMed ID: 11368960
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Behavioral indications for phenothiazine and benzodiazepine tranquilizers in dogs.
    Hart BL
    J Am Vet Med Assoc; 1985 Jun; 186(11):1192-4. PubMed ID: 2861189
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Are benzodiazepines really anxiolytic? Evidence from a 3D maze spatial navigation task.
    Ennaceur A; Michalikova S; van Rensburg R; Chazot PL
    Behav Brain Res; 2008 Mar; 188(1):136-53. PubMed ID: 18055029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differences in the development of tolerance to various benzodiazepines.
    Nowakowska E; Chodera A; Cenajek-Musiał D; Szczawińska K
    Pol J Pharmacol Pharm; 1987; 39(3):245-52. PubMed ID: 2894019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The antinicotinic effects of drugs with clinically useful sedative-antianxiety properties.
    Aceto MD
    Pharmacology; 1975; 13(5):458-64. PubMed ID: 1803
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacological validation of a novel animal model of anticipatory anxiety in mice.
    Lecci A; Borsini F; Volterra G; Meli A
    Psychopharmacology (Berl); 1990; 101(2):255-61. PubMed ID: 1971957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GABA(A) receptor alpha-1 subunit deletion alters receptor subtype assembly, pharmacological and behavioral responses to benzodiazepines and zolpidem.
    Kralic JE; O'Buckley TK; Khisti RT; Hodge CW; Homanics GE; Morrow AL
    Neuropharmacology; 2002 Sep; 43(4):685-94. PubMed ID: 12367614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The behavioural properties of CI-988, a selective cholecystokininB receptor antagonist.
    Singh L; Field MJ; Hughes J; Menzies R; Oles RJ; Vass CA; Woodruff GN
    Br J Pharmacol; 1991 Sep; 104(1):239-45. PubMed ID: 1686205
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Some behavioural effects of carbamazepine - comparison with haloperidol.
    Nowakowska E; Kus K; Czubak A; Glowacka D; Matschay A
    J Physiol Pharmacol; 2007 Jun; 58(2):253-64. PubMed ID: 17622695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antagonism of behavioural depression produced by clonidine in the Mongolian gerbil: a potential screening test for antidepressant drugs.
    Kostowski W; Malatyńska E
    Psychopharmacology (Berl); 1983; 79(2-3):203-8. PubMed ID: 6133304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neurobehavioural evaluation of resveratrol in murine models of anxiety and schizophrenia.
    Magaji MG; Iniaghe LO; Abolarin M; Abdullahi OI; Magaji RA
    Metab Brain Dis; 2017 Apr; 32(2):437-442. PubMed ID: 27878417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.